Soleus Capital Management’s AYTU BioPharma AYTU Stock Holding History

Soleus Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-698	Closed	-$209K	–	63
2020 Q1	$209K	Buy	+698	New	+$135K	0.24%	44

Other funds holding AYTU

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Soleus Capital Management's AYTU Position: Q2 2020 in Review

Soleus Capital Management sold out of AYTU BioPharma (AYTU) in Q2 2020, closing a stake of 698 shares — an estimated $209K sold.

Soleus Capital Management first reported a position in AYTU in Q1 2020 and held it in 1 quarter. The position peaked at $209K in Q1 2020. 66 funds tracked by Wall St. Rank hold AYTU as of Q2 2020.

Soleus Capital Management reported no remaining AYTU BioPharma position as of Q2 2020 after selling out during the quarter.
Soleus Capital Management sold 698 AYTU BioPharma shares in Q2 2020, an estimated $209K.
Soleus Capital Management first reported a position in AYTU BioPharma in Q1 2020 and held it in 1 quarter.
Soleus Capital Management's AYTU BioPharma position peaked at $209K in Q1 2020.
66 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2020.

Based on Soleus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.